Knowledge Insight: Pan-Specific Antibodies Uncover Conserved Post-Translational Modification Regulatory Networks in Cancer
Knowledge Insight: Pan-Specific Antibodies Uncover Conserved Post-Translational Modification Regulatory Networks in Cancer
Concept
Post-translational modifications (PTMs) are dynamic, reversible chemical alterations of amino acid residues that govern protein activity, stability, localization, and protein–protein interactions. Key PTM types include phosphorylation, acetylation, ubiquitination, and methylation. Pan-specific PTM antibodies are reagents that recognize conserved modification motifs (e.g., acetyl‑lysine) across diverse protein contexts, enabling global analysis of modification states.
Research Frontier
Current cancer research is shifting from single‑pathway or single‑PTM studies to pan‑cancer, multi‑PTM integrated omics. This paradigm uses large‑scale proteomic profiling across multiple tumor types to identify conserved signaling modules, prognostic biomarkers, and actionable therapeutic nodes. Pan‑specific antibodies are essential tools for enrichment, screening, validation, and clinical translation.
Research Significance
PTMs act as molecular switches that drive oncogenic signaling, metabolic reprogramming, and therapy resistance. Systematic analysis of PTM networks:
- Reveals universal mechanisms underlying cancer hallmarks
- Identifies conserved diagnostic and prognostic biomarkers
- Uncovers actionable targets for broad‑spectrum therapeutics
- Bridges basic proteomic discovery to clinical companion diagnostics
Core Mechanisms & Research Methodology
Why PTM Networks Drive Malignancy
- Oncogenic mutations rewire kinase, acetylase, and ligase activities
- Multiple PTMs crosstalk to coordinate proliferation, survival, and invasion
- Conserved PTM modules operate across diverse cancer types
Value of Pan‑Specific Antibodies
- Global PTM Enrichment: Antibody‑based affinity purification enables unbiased MS‑based PTM profiling
- High‑Throughput Screening: Antibody arrays support pan‑cancer PTM landscape mapping
- Functional Validation: IF, IP, and ChIP assays characterize subcellular localization and interactions
- Clinical Translation: IHC and quantitative immunoassays support biomarker validation
Key Pan‑Cancer PTM Findings
- Conserved PTM modules regulate cell cycle, DNA repair, and metabolism across tumor types
- Specific PTM levels correlate with tumor stage, grade, and patient prognosis
- Modified hub proteins represent high‑value therapeutic targets
Product Empowerment
ANT BIO PTE. LTD. provides the Acetyl‑Lysine Rabbit Polyclonal Antibody (Cat. No. S0B0655) under its Starter product line. This pan‑specific reagent enables robust, high‑sensitivity detection of acetylated proteins across biological systems.
It is widely used for global acetyl‑proteome studies, epigenetic analysis, signaling research, and drug discovery—making it indispensable for investigating pan‑cancer PTM regulatory networks.
Core Product Advantages
表格
|
Core Product Advantages |
|
High Specificity & Broad Recognition: Specifically binds acetyl‑lysine residues with minimal cross‑reactivity to non‑modified lysine, methylation, or ubiquitination; recognizes diverse acetylated proteins. |
|
Strong Affinity & Sensitivity: Affinity‑purified for high performance; reliably detects low‑abundance acetylated proteins with low background in WB and other assays. |
|
Multiplex Application Compatibility: Validated for WB, IP, IF/ICC, and ChIP; supports multi‑modal PTM research. |
Key Application Values
表格
|
Key Application Values |
|
Global Acetyl‑Proteome Analysis: Enrichment and quantification of acetylated proteins for pan‑cancer screening. |
|
Epigenetic Research: Histone acetylation profiling and transcriptional regulation studies. |
|
Signaling & Metabolism: Investigation of acetylation‑dependent kinase, p53, NF‑κB, and metabolic pathway control. |
|
Drug Discovery: Screening and validation of HAT/HDAC inhibitors and targeted therapeutics. |
|
Disease Mechanism Research: Exploration of acetylation dysregulation in cancer, neurodegeneration, and metabolic disorders. |
Brand Mission
ANT BIO PTE. LTD. is a leading provider of life science reagents, offering antibodies, recombinant proteins, assay kits, and general laboratory reagents. We operate three specialized sub‑brands: Absin (general reagents & kits), Starter (antibodies), and UA (recombinant proteins), delivering integrated solutions for proteomics, oncology, epigenetics, and translational research. We are committed to supplying high‑quality, consistent, and innovative tools to advance global understanding of PTM networks and accelerate precision medicine.
Related Product List
表格
|
Product Name |
Catalog No. |
Applications |
|
Acetyl‑Lysine Rabbit Polyclonal Antibody |
S0B0655 |
WB, IP, IF, ChIP, acetyl‑proteome enrichment |
|
Pan‑Phospho‑Ser/Thr/Tyr Antibody Panel |
Starter series |
Global phosphorylation analysis |
|
Acetylation Detection Kits |
Absin series |
Quantitative PTM assays |
|
Recombinant Histone Proteins |
UA‑series |
PTM validation and binding assays |
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
